Can diabetic medications cause rheumatic manifestations
• Thiazolidinediones (rosiglitazone, pioglitazone) and sodium-glucose cotransporter-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) have been associated with increased fractures and loss of bone density.
• Dipeptidyl peptidase-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) have been reported to cause severe arthralgias and myalgia. These symptoms were described in post-marketing data, suggesting a low prevalence of this potential side effect. Nonetheless, the Food and Drug Administration has published a safety announcement regarding this potential side effect and advises clinicians to monitor for joint and muscle symptoms during therapy.
